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Abstract
Physical exercise has demonstrated benefits for managing nonalcoholic fatty
liver disease (NAFLD). However, in daily life maintaining exercise without help
may be difficult. A whole-body vibration device (WBV) has been recently
introduced as an exercise modality that may be suitable for patients who have
difficulty engaging in exercise. We tested WBV in patients with NAFLD and
estimated its effectiveness. We studied the effects of a 6-month WBV program
on hepatic steatosis and its underlying pathophysiology in 25 patients with
NAFLD. Seventeen patients with NAFLD were designated as a control group.
After WBV exercise, body weight in the study group decreased by only 2.5%
compared with the control group. However, we found significant increases
in muscle area (+2.6%) and strength (+20.5%) and decreases in fat mass
(6.8%). The hepatic (9.9%) and visceral (6.2%) fat content also signifi-
cantly decreased (P < 0.05). There was substantial lowering of hepatic stiff-
ness (15.7%), along with improvements in the levels of inflammatory
markers; tumor necrosis factor alpha (50.9%), adiponectin (+12.0%), ferritin
(33.2%), and high-sensitivity C-reactive protein (43.0%) (P < 0.05). These
results suggest that WBV is an exercise option for patients with NAFLD that is
effective, efficient, and convenient.
Introduction
Nonalcoholic fatty liver disease (NAFLD) is a highly
prevalent disease that presents on a spectrum ranging
from asymptomatic simple steatosis to nonalcoholic
steatohepatitis (NASH). It often advances to fibrosis and
cirrhosis (Angulo 2002). NAFLD is the most common
cause of abnormal liver function observed in clinical
practice, and is a well-described cause of metabolic abnor-
malities (Angulo 2002; Targher et al. 2006). Nevertheless,
treatment options for NAFLD are limited. Until recently,
there has been a paucity of evidence in favor of pharma-
cological and surgical treatments for NAFLD (Sasaki et al.
2014; Hardy et al. 2015). Many such approaches are too
expensive and risky to be attempted in NAFLD patients.
However, lifestyle management by diet and/or exercise
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aimed at weight loss has been demonstrated to be effec-
tive as a first-line therapy (Harrison and Day 2007; Musso
et al. 2012).
The specific effects of exercise have received a great
deal of attention. Our previous studies (Oh et al. 2013,
2017) and those of others (Keating et al. 2015a) have
clearly demonstrated the therapeutic effects of exercise
regardless of detectable reductions in body weight. In
addition, epidemiological studies have shown that higher
levels of physical activity are associated with a lower risk
of NAFLD (Rector and Thyfault 2011), and have also
shown an inverse correlation between risk factors for
NAFLD and cardiorespiratory fitness (Spassiani and Kuk
2008). It would appear obvious that exercise regimens are
indispensable for managing NAFLD.
In the absence of specific exercise guidelines for
NAFLD, various modalities and intensities of exercise
have been explored (including aerobic-type jogging, walk-
ing and cycling, resistance-type exercise using dumbbells
and barbells, and weight machines) (Keating et al. 2015a;
Oh et al. 2014, 2015a,b). Studies involving these modali-
ties have demonstrated some success. However, in daily
life, maintaining these exercise routines without expert
help may be difficult, due to insufficient time, risk of
injury, boredom, and fatigue. Especially for obese and/or
older patients with NAFLD, care must be taken with
regard to mechanical factors, including hip and knee
joints, as well as physiological factors including regulation
of cardiac output and blood pressure (McArdle et al.
2010). Thus, such exercise may not be indicated for all
patients with NAFLD.
Whole-body vibration (WBV) has been recently intro-
duced as a novel alternative. This exercise passively gener-
ates intense stimulation to produce dynamic changes in
muscle fiber length through tonic vibration reflex. The
technique uses rapid and repeated oscillations transmitted
from a vibration device while the patient stands or sits on
a platform. This form of exercise elicits strong stimulation
of muscles with brief exposure to vibration (Cochrane
2010). Many previous studies have reported the efficacy
of WBV in various fields of medicine and physiology
(Cochrane 2010). WBV may be a suitable exercise
approach for patients who have difficulties in engaging in
general exercise due to its effectiveness and convenience
of use.
In this study, we evaluated the effectiveness and useful-
ness of WBV in the management of patients with NAFLD,
as an extension of a previous pilot study (Sumida et al.
2015). We conducted a 6-month supervised WBV pro-
gram and analyzed its effects on hepatic steatosis and stiff-
ness, liver function tests, body adiposity, and metabolic
parameters. We compared the outcomes with those of
control patients with NAFLD who did not undergo the
exercise regimen. In a separate analysis, to obtain specific
information regarding the advantages of WBV, we mea-
sured markers of oxidative stress and inflammation,
adipokines, morphological changes, and functional
changes (ectopic fat deposition, muscle strength, and Bio-
dex measurements), in patients with NAFLD who partici-
pated in the WBV program.
Methods
Study subjects
Forty-five NAFLD patients who had difficulty engaging in
regular exercise were recruited by physicians specializing
in lifestyle-related liver diseases in an outpatient depart-
ment at the University of Tsukuba Hospital, Ibaraki pre-
fecture, Japan, between January 2014 and December 2016.
Specifically, patients were recruited whose NAFLD had
been worsening, despite lifestyle counseling as part of a
routine long-term program offered by the hospital (mean
>1 year). Each patient met the following inclusion crite-
ria: NAFLD, according to the diagnostic guidelines of the
Asia-Pacific region (Chitturi et al. 2007); no signs or
symptoms of heart disease; sedentary lifestyle (exercise
frequency: ≤1 session per week and ≤30 min per session)
over the past year; age ≥20 but ≤70; alcohol consumption
<20 g per day; no other causes of liver disease; no suspi-
cion of liver cirrhosis (Castera et al. 2008), assessed by
elastography (<12.5 kPa); and with permission to exercise
from their physician.
Of the recruited patients, 25 participated in the WBV
program for 6 months as the WBV group (four men and
21 women; mean age: 54.2 years) and all completed it. In
addition, another 20 patients participated in the study as
the control (CON) group. This group received 12–24 ses-
sions of lifestyle counseling regarding diet and physical
activity, conducted by a registered dietitian and a physi-
cian specializing in nutrition, over the 6-month period.
This counseling is conducted as part of the routine man-
agement undertaken at the hospital. Three patients
dropped out of the study from the CON group (one
abandoned the study and two dropped out because of
lack of time). Accordingly, we analyzed data from 17
patients with NAFLD (five men and 12 women; mean
age: 48.4 years) in the CON group. All the measurements
were made prior to and 5 days after the completion of
the intervention. To ensure accuracy, we asked all the
patients to avoid exercise during the previous day and to
fast overnight for 12 h (water intake was permitted)
before the measurements. All measurements were carried
out during the morning at 10.
This study was approved by the Institutional Review
Board of the University of Tsukuba Hospital and
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retrospectively registered with the University Hospital
Medical Information Network Clinical Trials Registry
(UMIN-CTR ID no: R000034782, 19, December 2017).
The programs were carried out in accordance with the
principles of the 1975 Declaration of Helsinki, and all
subjects signed informed consent documents prior to
participation in this study.
WBV program
For this study, we used a WBV program with its intensity
and time modified from a previous pilot study (Oh et al.
2014): the strength was slightly increased, and the dura-
tion was reduced by half. The patients in the WBV group
visited the rehabilitation division of Tsukuba University
Hospital and underwent a WBV program designed to
train the upper and lower body using the following three
procedures: (1) Preparation: hamstring stretch, calf
stretch, side stretch, and hip joint stretch (frequency: 30–
35 Hz, amplitude: low, time: 30 sec, number: 1); (2)
Strength and power: deep squat, wide stance squat, lunge,
push up, triceps dip, crunch, front plank, and pelvic
bridge (frequency: 30–35 Hz, amplitude: low, time:
30 sec, number: 1); (3) Massage: calf, hamstring, lower
back, shoulder, and face (frequency: 40–50 Hz, amplitude:
high, time: 30 sec, number: 1); using a Power Plate Pro-6
(Badhoevendorp, Netherlands) and lasting a total of
~20 min (≥53 kcal, ≤76 kcal), without a rest interval after
each movement, twice a week for 6 months.
The maximum pulse rate of the patients increased in
proportion to the exercise intensity involved in each pro-
cedure versus their resting pulse rate (preparation session:
+11 bpm, strength and power session: +45 bpm, massage
session: +16 bpm) (OH1, Polar Electro Inc., Bethpage,
NY). Their systolic (mean 6.2 mmHg) and diastolic
(mean 1.6 mmHg) blood pressures were reduced during
the WBV program (HEM-770A, Omron Health Care,
Kyoto, Japan).
Figure 1 displays details of the WBV program. The
procedures were carried out with the assistance of certi-
fied professional trainers and under the supervision of a
study physician.
In our previous pilot study (Oh et al. 2014), we identi-
fied a number of problems related to the capability and
willingness of patients to perform WBV exercise, and we
modified the protocol to avoid these in the present study.
Our staff has a great deal of experience of exercise inter-
vention studies, and our WBV trainers have all been
trained in the specific exercises involved and are highly
specialized, with a lot of field experience. They assisted
the patients on a one-to-one basis and corrected their
positions to provide maximum stimulation to each of
the appropriate muscles. For example, in the case of
push-ups, the knees were placed on the floor and the load
of their body weight was placed on their arms, which
leads to gradual achievement of the proper posture. In
addition, the load encountered while undertaking reverse
push-ups was controlled by setting an appropriate angle
for the elbow to be flexed, by adjusting the space between
the hands and legs. The proper posture and stability of
patients with muscular deficits was ensured during virtu-
ally all body movements by the trainer. Because patients
with NAFLD often have an enormous variety of different
symptoms, it is important for the purposes of treatment
that they are assisted by a professional trainer. The sub-
jects were asked not to participate in any lifestyle counsel-
ing, and to maintain their normal diet and exercise
routines.
Anthropometry and body composition
Height was measured with a wall-mounted stadiometer
(Muratec-KDS, Kyoto, Japan). Body weight, fat mass,
skeletal muscle mass, and abdominal visceral fat area were
analyzed using an InBody720 (Biospace Japan, Tokyo,
Japan), with the fasted patients being dressed in light
clothing, after urinating, and after 10 min in a standing
position. BMI was calculated (kg·m2) using these data.
We calculated a new surrogate marker for NAFLD, “skele-
tal muscle mass to visceral fat area ratio” (SV-ratio)
(Moon et al. 2013) in units of g·cm2.
Laboratory determinations
Blood was drawn from the right median cubital vein
using a butterfly needle at baseline and at the sixth month
while the patient was fasting. Serum and plasma samples
were separated using low-speed centrifugation (Tokyo,
Japan). We measured triglyceride (TG), total cholesterol
(TC), low-density lipoprotein cholesterol (LDL), and free
fatty acid (FFA) levels as follows: aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), and
gamma-glutamyl transpeptidase (cGT) using the Japan
Society of Clinical Chemistry transferable method;
Hyaluronan (HA) and plasma type IV collagen using the
latex agglutination method; plasma insulin and ferritin
levels using a chemiluminescent immunoassay method;
and plasma glucose levels using the hexokinase-G-6-PDH
method. For the 25 subjects who completed the WBV
program, we evaluated serum levels of thiobarbituric
acid reactive substances (TBARS; Cayman, Ann Arbor,
USA), tumor necrosis factor alpha (TNF-a), interleukin
6 (IL6) and leptin (R&D Systems; Minneapolis, USA),
M30 (Peviva AB, Bromma, Sweden), high-sensitivity C-
reactive protein (hsCRP; Calbiotech, Spring Valley, USA),
and adiponectin (Sekisui Medical, Tokyo, Japan) using
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commercial enzyme-linked immunosorbent assay kits.
Other markers included the homeostatic model assess-
ment-insulin resistance (HOMA-IR), used to quantify
insulin resistance (Matthews et al. 1985) and the NAFLD
fibrosis score, used to measure degree of liver fibrosis
(Angulo et al. 2007).
Assessment of Fibroscan and magnetic
resonance spectroscopy (1HMRS)
Hepatic stiffness was determined using Fibroscan (Echo-
sens, Paris, France) with a 3.5 MHz standard probe. Details
regarding the method have been published previously (San-
drin et al. 2003). Hepatic fat quantity was determined with
a controlled attenuation parameter (CAP) designed to eval-
uate hepatic ultrasonic attenuation with a 3.5 MHz stan-
dard probe, using signals acquired by the Fibroscan.
Detailed procedures have also been published previously
(Sasso et al. 2010). Muscle area, intramyocellular lipids
(IMCL), extramyocellular lipids (EMCL) in both quadri-
ceps muscles, and intrahepatic lipids (IHL) were used to
calculate the ratio of the intrahepatic fat signal to water sig-
nal (lipid·water-1). These parameters were analyzed using a
3-tesla magnetic resonance device (Achieva; Philips Elec-
tronics Japan, Tokyo, Japan) equipped with a 6-channel
Torso coil, as previously described (Sumida et al. 2014).
The acquired data were analyzed with LCModel software
(LA Systems, Tokyo, Japan).
Figure 1. The program chart for whole-body vibration exercise.
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Muscle strength
Isometric knee flexion and extension strength was deter-
mined using a Biodex System III dynamometer (Biodex
Medical Systems, Shirley, USA). The knee was extended to
an angle of 60° in a seated position to produce maximal
power of the quadriceps with close-to-optimum muscle
lengths. Peak torque (Nm) consisting of three maximal
efforts was determined as the maximal strength. Each iso-
metric contraction was maintained for 3 seconds. The results
were normalized to body weight (Kg) (Oh et al. 2015a,b).
Statistical analysis
Statistical analysis was conducted using the Statistical
Package for the Social Sciences (SPSS) for Windows, ver-
sion 23.0 (IBM, Armonk, USA). Descriptive values were
presented as mean  standard error (SE) or standard
deviation (SD), or log transformations for skewed vari-
ables. Analysis of categorical parameters was conducted
using the chi-squared test. For analysis of significant dif-
ferences in baseline among the groups, the one-way analy-
sis of variance (ANOVA) test was used. To evaluate
significant changes (at baseline and at 6 months) in clini-
cal values within each group, we conducted paired t tests.
Significant differences between groups (CON group vs.
WBV group) were evaluated using either independent t
tests test or analysis of covariance (ANCOVA). P < 0.05
was considered statistically significant.
Results
A total of 42 patients with NAFLD participated, including
17 in the CON group and 25 in the WBV group. The
attendance rate was 89.3% in the WBV group. Patients in
the WBV group were further analyzed to determine the
effects of WBV training on NAFLD pathophysiology,
including measurements of intramyocellular and intrahep-
atic lipid deposition, muscle area and strength, adipoki-
nes, apoptosis, inflammation, and oxidative stress.
Baseline characteristics
At baseline, there were no significant differences between
groups in terms of age, alcohol consumption, and smoking.
In addition, no measurements, including anthropometry,
ectopic fat, hepatic stiffness, liver function test, insulin resis-
tance, and lipid profile (with the exception of LDLC) were
statistically different between the CON and WBV groups.
Anthropometry
Table 1(a) displays anthropometry for each group during
the study period. In the WBV group, comparing baseline
Table 1. The outcomes of anthropometry and body composition, metabolic parameters (Insulin Resistance and Lipid Profile) values in a total
of 42 subjects with NAFLD.
CON WBV
CON vs.
WBV
n = 17 n = 25
Pre Post Change P Pre Post Change P P
(a) Anthropometry and body composition
BMI, kg m2 29.2  5.5 29.3  5.4 +0.1 0.863 29.9  6.9 29.2  6.6 0.7 0.008 0.010
Body weight, kg1 78.4  24.6 78.3  24.4 0.1 0.791 76.3  16.2 74.4  15.9 1.9 0.005 0.009
Fat mass, kg1 29.4  12.0 30.2  12.2 +0.7 0.026 30.9  12.2 28.8  11.7 2.1 0.000 0.000
SVR 200.5  64.3 190.1  58.4 10.4 0.001 197.0  49.0 212.6  55.1 +15.6 0.000 0.000
% Fat mass 37.0  5.8 38.0  6.0 +1.0 0.005 39.7  8.1 37.9  7.8 1.8 0.000 0.000
VAT area, cm2 129.4  31.3 133.7  31.4 +4.3 0.003 130.7  34.3 122.6  34.1 8.1 0.000 0.000
(b) Metabolic parameter
LogFPG 2.044  0.092 2.069  0.122 +0.025 0.040 2.059  0.130 2.040  0.092 0.019 0.205 0.039
LogFPI 1.066  0.389 1.032  0.428 0.034 0.412 1.028  0.270 0.976  0.341 0.052 0.356 0.795
LogHOMAIR 0.514  0.414 0.514  0.453 0.000 0.994 0.480  0.352 0.409  0.401 0.071 0.255 0.337
LDLC, mg dL1a 134.8  32.3 135.1  34.0 +0.3 0.972 114.8  27.6 109.9  25.6 4.9 0.097 0.547
LogTriglycerides 2.162  0.262 2.222  0.262 +0.060 0.108 2.084  0.198 2.040  0.200 0.044 0.150 0.030
LogFFA 1.781  0.131 1.758  0.178 0.023 0.458 1.792  0.134 1.706  0.141 0.110 0.001 0.025
Values are presented as the group means  SD. aANCOVA with adjustments for respective baseline values were applied to compare changed
values between groups. Abbreviations: CON, control group; WBV, whole-body vibration; BMI, body mass index; SVR, skeletal muscle mass to
visceral fat area ratio; VAT, visceral adipose tissue; FPG, fasting plasma glucose; FPI, fasting plasma insulin; HOMA-IR, insulin resistance by
homeostasis model; FFAs, LDLC, low-density lipoprotein cholesterol; FFA, free fatty acids.
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with the 6-month results, body weight decreased by 2.5%,
BMI by 2.3%, fat mass by 6.8%, SV-ratio increased by
7.9%, percentage fat mass decreased by 4.5%, and VAT
area decreased by 6.2%. In the CON group, we observed
significant changes in three parameters: fat mass increased
by 2.4%, SV-ratio decreased by 5.18%, percentage fat
mass increased by 2.7%, and VAT area increased by 3.3%
at 6 months. In the CON group, body weight was
unchanged by the end of the study. When a comparison
was made between the two groups, the magnitude of
changes in all anthropometric parameters was greater in
the WBV group compared with those of the CON group.
Ectopic fat, hepatic stiffness, and liver
function tests
Figure 2 shows the results of hepatic fat and stiffness for
the WBV group. Hepatic fat decreased by 10.0% at
6 months. In the CON group, hepatic fat increased by 2.9%
(not significant). The WBV group showed decreases in hep-
atic stiffness of 8.3%. All liver function tests improved in
the WBV group from the baseline to 6 months: AST
decreased by 8.5%, ALT decreased by 10.6%, and cGT
decreased by 7.8%. There were no statistical differences in
the CON group between the beginning and the end of the
study. When a comparison was made between the CON
and WBV groups, the magnitude of the decrease in levels of
all parameters was greater in the WBV group (P < 0.05).
Metabolic parameters
The results of changes in the insulin resistance and lipid
profile are displayed in Table 1(b). From baseline to 6
months, FPG increased by 1.2% in the CON group, while
no increase was observed in the WBV group. No other
parameter showed a significant change in either the CON
or the WBV group. In addition, metabolic parameters
were not significantly different between the two groups.
On lipid profile analysis, FFA decreased by 16.8% in
the WBV group. The other parameters did not signifi-
cantly change in either the CON group or the WBV
group over the course of the study. However, a
Figure 2. Changes in levels of hepatic steatosis and stiffness (A), liver function tests (B), from the baseline to the end point of 12 weeks in 25
subjects with NAFLD who participated in a 6-month whole-body vibration exercise program.
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comparison between the groups revealed that the magni-
tude of the decrease in triglycerides and FFA levels were
greater in the WBV group than in the CON group
(P < 0.01).
Intramyocellular and intrahepatic lipid
deposition
Figure 3 shows the results of changes in IMCL and EMCL
(B) and IHL (C) assessed using 1HMRS for the WBV
group during the intervention period. 1HMRS analysis
revealed significant decreases IHL levels (21.7%) in the
WBV group. However, IMCL levels in the quadriceps
showed no significant changes.
Muscle area and strength
Figure 3A shows the results of changes in muscle area
assessed by 1HMRS analysis and muscle strength using Bio-
dex in the quadriceps for the WBV group after 6 months.
Figure 3. Changes in skeletal muscle area and strength in quadriceps (A), extra-, intramyocellular lipids (B), and intrahepatic lipids (C) from
baseline to 6 months in 25 subjects with NAFLD who participated in a 6-month whole-body vibration exercise program. Abbreviation: IMCL,
intramyocellular lipids; IHL, intrahepatic lipids.
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In addition to a significant increase in skeletal muscle
area of the quadriceps by 2.7%, muscle strength in the
quadriceps increased by 18.4%.
Adipokines, apoptosis, inflammation, and
oxidative stress
Serum markers of adipokines (TNFa, IL6, adiponectin,
and leptin), oxidative stress (TBARS), hepatic inflamma-
tion (ferritin and HsCRP), and hepatocyte apoptosis
(M30) were determined in the WBV group (Fig. 4). After
the WBV program, significant changes were observed in
three parameters: TNFa decreased by 50.8%, adiponectin
increased by 7.9%, ferritin decreased by 18.0%, and
HsCRP decreased by 14.5%. There were no significant
changes in levels of IL6, leptin, TBARS, or M30.
Discussion
The patients with NAFLD who underwent the WBV pro-
gram for 6 months showed a modest decrease in body
weight (Table 1a). Weight reduction is generally accepted
to be the most effective therapy for NAFLD in clinical
practice (Harrison and Day 2007). Many studies have
suggested that an approximate 3–10% reduction in weight
alters liver function tests, metabolic abnormalities, and
the degree of hepatic steatosis (Keating and Adams 2016).
In this study, a weight reduction of only 2.5% was
observed in the WBV group. However, we noted signifi-
cant improvements in muscle area and strength in the
quadriceps muscle (Fig. 3) coupled with an increased SV-
ratio and decreased levels of whole-body fat mass
(Table 1a). Moreover, we observed considerable decreases
in ectopic fat deposition, hepatic fat content (Fig. 2), IHL
(Fig. 3C), VAT (Table 1a), FPG, and FFA (Table 1b). In
the WBV group, there was improvement with respect to
hepatic stiffness (Fig. 2), as well as the lowered levels of
inflammatory markers (TNFa, adiponectin, ferritin, and
hsCRP, Fig. 4). In addition, there were improvements in
liver function tests, including ALT, AST, and cGT
(Fig. 2). Recently, it has been demonstrated that exercise
meliorates NAFLD independent of detectable reductions
in body weight. This is not to say that weight reduction
is not very important in managing NAFLD. However,
our results suggest that WBV may be practical and effec-
tive for patients that have difficulty engaging in regular
exercise.
Skeletal muscle is the most abundant tissue of the
human body, comprising 40–50% of total body mass.
Skeletal muscle is not only the tool for mechanical move-
ments but also plays a significant role in glucose and fatty
acid metabolism regulating insulin sensitivity (Turcotte
and Fisher 2008). Furthermore, skeletal muscle acts as a
secretory organ for myokines (Pedersen 2013), which
mediate crosstalk between various organs, including liver
and adipose tissue. Bogaerts et al. (2007) and Machado
Figure 4. Changes in levels of adipokines (A), inflammation (B) and markers of apoptosis and oxidative stress (C), from baseline to 12 weeks in
25 subjects with NAFLD who participated in a 6-month whole-body vibration exercise program. Abbreviation: TNF-a, tumor necrosis factor
alpha; TBARS, thiobarbituric acid reactive substances; IL6, interleukin 6; hsCRP, high-sensitivity CRP.
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et al. (2010) performed randomized controlled trials
showing that WBV in elderly patients produces an explo-
sive increase in muscle size and strength via strong eccen-
tric overload generated by the vibration. This result
compared favorably with a general exercise program (Ste-
wart et al. 2014), consistent with our results. Although
controversial, it has been reported that WBV alters steroid
and growth hormones related to muscle hypertrophy,
such as increases in testosterone, growth hormone, and
insulin-like growth factor 1, as well as decreases in corti-
sol (Domingos et al. 2015). Positive changes in these hor-
mones induced by WBV may lead to significant
improvement in muscle size and strength. Interestingly,
the pathological conditions associated with NAFLD have
been closely linked to testosterone (Kim et al. 2012),
growth hormone (Takahashi et al. 2007), insulin-like
growth factor 1 (Sumida et al. 2015), and cortisol (Tar-
gher et al. 2006). WBV may be partially responsible for
the activation of the myokine irisin, which transforms
white fat cells into brown fat (Huh et al. 2014). The
strong vibration of muscle WBV mimics the normal cold
response, giving rise to increases in irisin levels (Huh
et al. 2014). It was reported that increased irisin levels
parallel increases in testosterone and insulin-like growth
factor 1(Huh et al. 2014), and is inversely related with
degree of hepatic steatosis (Zhang et al. 2013). Therefore,
the increased muscle size and strength stimulated by
WBV might be a key factor in reversing pathology in
NAFLD patients.
Excessive VAT deposition may be causally related to
insulin resistance via the elaboration of excessive FFAs
and abnormal adipokine balance. Koda et al. (2007)
reported that visceral fat may be the most important risk
factor for progression of NAFLD. We found that WBV
improved levels of VAT as well as skeletal muscle in
patients with NAFLD. WBV may lead to the improve-
ment of systemic glucose and fatty acid metabolism, as
well as that of adipokines. We suggest that improved
levels of VAT (Despres and Lemieux 2006) and adiponec-
tin (Kim et al. 2007) in our study may be associated with
functional improvements in adipose tissue. These changes
may reverse insulin resistance in adipose tissue, which
would in turn inhibit the “lipotoxic” environment, and
would lead to reduction in systemic levels of FFAs in
patients with NAFLD in their daily life (Morigny et al.
2016). In addition, during WBV, circulating FFAs broken
down in systemic adipose tissues and liver could be used
to produce energy (Turcotte et al. 1992). Similarly, our
observation of decreased levels of FPG may explain the
observation of increased sensitivity to insulin for glucose
uptake and continuous glycogen synthesis in active skele-
tal muscle (Robergs and Roberts 2000) during WBV. The
decreased FPG associated with WBV is equivalent to that
associated with other general exercise (Behboudi et al.
2011). A marked increased SV-ratio suggested the impor-
tance of skeletal muscle and visceral fat for the hepatic
aspects of NAFLD (Moon et al. 2013; Shida et al. 2017).
Consequently, in daily life, beneficial ability to suppress
lipolysis, and during WBV exercise, the availability of adi-
pose tissue in the liver to produce energy that might
otherwise contribute to hepatic steatosis.
Our previous study (Oh et al. 2017) and that of Kistler
et al. (2011) found that only high-intensity exercise
improved inflammatory markers and hepatic stiffness.
Therefore, the intensity of the exercise may be an impor-
tant factor. Another point in favor of the superiority of
WBV with respect to advanced fibrosis is the remarkable
improvement in inflammatory markers achieved. The
reductions in hepatic hsCRP and stiffness achieved in
patients undergoing the low-intensity WBV program sug-
gest that this may be considered the best program for
patients who have difficulty engaging in exercise. How-
ever, more specific and concrete measures, including liver
biopsy and histology, are required to confirm its efficacy.
Our results may help begin to describe the molecular
mechanisms mediating the effects of exercise on hepatic
inflammation and fibrosis. First, in NAFLD patients, a
great amount of iron accumulation in the liver has been
observed. When combined with imbalanced adipokine
secretion, this could stimulate development of inflamma-
tion and progression of liver fibrosis. Thus, the decreased
level of serum ferritin resulting from 6-month WBV exer-
cise may contribute to the reduction of hepatic stiffness.
Second, Savvidou et al. (2009) demonstrated that low
serum adiponectin levels are a predictive factor of
advanced fibrosis in the liver based on histologic parame-
ters in biopsy-proven NAFLD. Ding et al. (2005) found
that adiponectin protects against hepatic advanced fibrosis
via hepatic stellate cell apoptosis mediated by induction
of caspase activation and inhibition of proliferation.
Another possible explanation was suggested by Wigg et al.
(2001), who reported high serum TNFa levels in patients
with NASH. TNFa interferes with insulin signaling via
accelerating hepatic steatosis and proinflammatory mark-
ers, contributing to progression of NASH (Crespo et al.
2001). Therefore, our study showed that the remarkable
improvement of hepatic stiffness likely contributed to
raised serum adiponectin levels and reduced serum TNFa
levels as a result of WBV.
Ectopic fat in skeletal muscle and the liver has been
shown to cause insulin resistance associated with NAFLD
via impaired insulin signaling by diacylglycerol activation
of protein kinase C50. We assessed pre–post-WBV levels
of IMCL and IHL using (1H) MRS. We found signifi-
cant improvement of IHL, but not of IMCL levels.
Although, many diabetes studies have demonstrated a
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stronger relationship between IMCL and insulin resis-
tance in muscle, there continues to be a debate regard-
ing the notion of the “athletic paradox” (Goodpaster
et al. 2001) in the field of sports science. Briefly, despite
the fact that trained athletes show elevated IMCL levels,
they have noticeable insulin sensitivity and large oxida-
tive capacity. This notion may apply to our observation
of unchanged IMCL levels in the WBV group. WBV
may allow preservation of local energy sources and
increased oxidative capacity. In addition, WBV leads to
considerable improvement in the degree of IHL in
patients with NAFLD. Fabbrini et al. (2009) emphasized
that IHL levels are among the most important indicators
of metabolic abnormalities, including VAT levels.
Increased IHL aggravates insulin resistance and increases
hepatic very-low-density lipoprotein (VLDL) secretion
rate. In addition, FFAs released by lipolysis of IHL
increased hepatic VLDL production rate via an autocrine
mechanism (Fabbrini et al. 2008). IHL was associated
with hepatic glucose release, and correlated negatively
with hepatic glycogen stores (Krssak et al. 2004). There-
fore, noticeable reduction in IHL due WBV may be con-
sidered to be associated with improved liver function. In
this regard, we observed improved liver function tests
(AST, ALT, and cGT) (Laker 1990) and amelioration of
insulin resistance (Wallace et al. 2007).
The positive effects of general aerobic or resistance
exercise are supported by evidence from many clinical tri-
als on NAFLD pathophysiology. It appears that 4–
12 weeks of aerobic (Johnson et al. 2009; Finucane et al.
2010; Van der Heijden et al. 2010; Keating et al. 2015b;
Oh et al. 2017) or resistance (Hallsworth et al. 2011; Zel-
ber-Sagi et al. 2014; Oh et al. 2017) exercise led to a great
improvement in the liver fat content, which is associated
with metabolic comorbidities, compared with 24 weeks
on our WBV program. These results may raise questions
about the effectiveness of the WBV program. However,
we recruited patients for this study whose NAFLD was
worsening despite the lifestyle counseling that had been
offered by the hospital for more than 1 year and most
patients had difficulty engaging in general exercise
because of physiological burdens. The patients’ attendance
rate was about 90% for 6 months and they all completed
the WBV program for 6 months without any injuries and
medical problems. These study results may show a small
improvement using WBV compared with general exercise.
However, because WBV was considered to be a good
alternative exercise method, patients, if they wished, could
continue their exercise safely, conveniently, and efficiently
in the hospital . However, it should be noted that there is
currently little scientific evidence for the benefits of WBV
and the optimal dose and modality for exercise therapy in
NAFLD patients.
However, there were a few limitations to this study.
First, it should be noted that the research protocol was
not designed as a randomized controlled trial. The clinal
trial was retrospectively registered because of an error.
Overall, causality cannot be inferred from our results and
there is a risk of bias. Second, we did not quantify daily
energy intake and expenditure in this study. Although the
subjects were asked not to participate in any lifestyle
counseling and to maintain their normal diet and exercise
routines. It would have aided the interpretation to quan-
tify these outcomes. Finally, the lack of histological data
prevented the evaluation of changes in the severity of
NAFLD and fibrosis during the study.
In summary, we have shown that WBV provided benefit
with respect to halting progression of NAFLD via reducing
ectopic fat deposition in the liver and intra-abdominal sites,
as well as improvements in muscle morphology and func-
tion. In addition, WBV reduced hepatic stiffness and its
related inflammatory markers that may contribute to
enhanced innate immunity and dysregulation of signaling
pathways in NAFLD. In short, these results demonstrate the
usefulness of WBV as an exercise option for patients with
NAFLD who have difficulty engaging in regular exercise.
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Our findings in this study suggest that WBV provided benefit with respect to halting progression of NAFLD via reducing
ectopic fat deposition in the liver and intra-abdominal sites, as well as improvements in muscle morphology and function.
In addition, WBV reduced hepatic stiffness and its related inflammatory markers that may contribute to enhanced innate
immunity and dysregulation of signaling pathways in NAFLD. These results demonstrated the usefulness of WBV as an
exercise option for patients with NAFLD who have difficulty engaging in regular exercise.
